{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "Concurrency And Parallelism in Python.ipynb",
      "provenance": [],
      "authorship_tag": "ABX9TyNM/DbBUKfFJNccJ9+BxhrV"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3CQ2PyX7iUq8"
      },
      "source": [
        "[Reference](https://medium.com/fintechexplained/advanced-python-concurrency-and-parallelism-82e378f26ced)"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MKZknuL4iTXS",
        "outputId": "d5def288-01ec-4944-d3c2-e667bc58992f"
      },
      "source": [
        "!pip install yfinance\n",
        "import yfinance as yf\n",
        "import time\n",
        "\n",
        "started = time.time()\n",
        "\n",
        "def print_company_info(company):\n",
        "    ticker = yf.Ticker(company)\n",
        "    info = ticker.get_info()\n",
        "    print(info)\n",
        "\n",
        "\n",
        "\n",
        "companies = ['ABT', 'ABBV', 'ABMD', 'ATVI', 'ADBE']\n",
        "for company in companies:\n",
        "    print_company_info(company)\n",
        "    \n",
        "    \n",
        "elapsed = time.time()\n",
        "\n",
        "print('Time taken: :', elapsed-started)"
      ],
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Collecting yfinance\n",
            "  Downloading https://files.pythonhosted.org/packages/7a/e8/b9d7104d3a4bf39924799067592d9e59119fcfc900a425a12e80a3123ec8/yfinance-0.1.55.tar.gz\n",
            "Requirement already satisfied: pandas>=0.24 in /usr/local/lib/python3.6/dist-packages (from yfinance) (1.1.4)\n",
            "Requirement already satisfied: numpy>=1.15 in /usr/local/lib/python3.6/dist-packages (from yfinance) (1.18.5)\n",
            "Requirement already satisfied: requests>=2.20 in /usr/local/lib/python3.6/dist-packages (from yfinance) (2.23.0)\n",
            "Requirement already satisfied: multitasking>=0.0.7 in /usr/local/lib/python3.6/dist-packages (from yfinance) (0.0.9)\n",
            "Collecting lxml>=4.5.1\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/64/28/0b761b64ecbd63d272ed0e7a6ae6e4402fc37886b59181bfdf274424d693/lxml-4.6.1-cp36-cp36m-manylinux1_x86_64.whl (5.5MB)\n",
            "\u001b[K     |████████████████████████████████| 5.5MB 6.9MB/s \n",
            "\u001b[?25hRequirement already satisfied: pytz>=2017.2 in /usr/local/lib/python3.6/dist-packages (from pandas>=0.24->yfinance) (2018.9)\n",
            "Requirement already satisfied: python-dateutil>=2.7.3 in /usr/local/lib/python3.6/dist-packages (from pandas>=0.24->yfinance) (2.8.1)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.6/dist-packages (from requests>=2.20->yfinance) (2020.6.20)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.6/dist-packages (from requests>=2.20->yfinance) (2.10)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.6/dist-packages (from requests>=2.20->yfinance) (3.0.4)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.6/dist-packages (from requests>=2.20->yfinance) (1.24.3)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.6/dist-packages (from python-dateutil>=2.7.3->pandas>=0.24->yfinance) (1.15.0)\n",
            "Building wheels for collected packages: yfinance\n",
            "  Building wheel for yfinance (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for yfinance: filename=yfinance-0.1.55-py2.py3-none-any.whl size=22618 sha256=ee7ae6d3ec0cc6d9af3657c1c6f1490d3fc50de7220eed179bb2c539b54e149f\n",
            "  Stored in directory: /root/.cache/pip/wheels/04/98/cc/2702a4242d60bdc14f48b4557c427ded1fe92aedf257d4565c\n",
            "Successfully built yfinance\n",
            "Installing collected packages: lxml, yfinance\n",
            "  Found existing installation: lxml 4.2.6\n",
            "    Uninstalling lxml-4.2.6:\n",
            "      Successfully uninstalled lxml-4.2.6\n",
            "Successfully installed lxml-4.6.1 yfinance-0.1.55\n",
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 107000, 'longBusinessSummary': \"Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '224 667 6100', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbott.com', 'maxAge': 1, 'address1': '100 Abbott Park Road', 'industry': 'Medical Devices', 'address2': 'Department 377 Building AP6A-1, Abbott park', 'previousClose': 113.06, 'regularMarketOpen': 113.67, 'twoHundredDayAverage': 100.25935, 'trailingAnnualDividendYield': 0.012736601, 'payoutRatio': 0.7447, 'volume24Hr': None, 'regularMarketDayHigh': 113.71, 'navPrice': None, 'averageDailyVolume10Day': 5414542, 'totalAssets': None, 'regularMarketPreviousClose': 113.06, 'fiftyDayAverage': 109.12278, 'trailingAnnualDividendRate': 1.44, 'open': 113.67, 'toCurrency': None, 'averageVolume10days': 5414542, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 1.44, 'exDividendDate': 1602633600, 'beta': 0.893461, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 109.75, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.04865, 'regularMarketVolume': 4318732, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 194551939072, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 5585046, 'priceToSalesTrailing12Months': 6.038048, 'dayLow': 109.75, 'ask': 110.49, 'ytdReturn': None, 'askSize': 1200, 'volume': 4318732, 'fiftyTwoWeekHigh': 115.14, 'forwardPE': 24.947725, 'fromCurrency': None, 'fiveYearAvgDividendYield': 1.89, 'fiftyTwoWeekLow': 61.61, 'bid': 109.69, 'tradeable': False, 'dividendYield': 0.0127, 'bidSize': 800, 'dayHigh': 113.71, 'exchange': 'NYQ', 'shortName': 'Abbott Laboratories', 'longName': 'Abbott Laboratories', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABT', 'messageBoardId': 'finmb_247483', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.655, 'beta3Year': None, 'profitMargins': 0.10496, 'enterpriseToEbitda': 27.409, '52WeekChange': 0.3477173, 'morningStarRiskRating': None, 'forwardEps': 4.4, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1772359936, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 17.709, 'sharesShort': 9924969, 'sharesPercentSharesOut': 0.0056, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.75431997, 'netIncomeToCommon': 3345999872, 'trailingEps': 1.891, 'lastDividendValue': 0.36, 'SandP52WeekChange': 0.16119564, 'priceToBook': 6.198543, 'heldPercentInsiders': 0.00696, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 2.03, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1758820739, 'enterpriseValue': 214424207360, 'threeYearAverageReturn': None, 'lastSplitDate': 1357084800, 'lastSplitFactor': '10000:4798', 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.283, 'dateShortInterest': 1604016000, 'pegRatio': 2.39, 'lastCapGain': None, 'shortPercentOfFloat': 0.0057, 'sharesShortPriorMonth': 9437987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 113.67, 'logo_url': 'https://logo.clearbit.com/abbott.com'}\n",
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 47000, 'longBusinessSummary': \"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '847 932 7900', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbvie.com', 'maxAge': 1, 'address1': '1 North Waukegan Road', 'industry': 'Drug Manufacturers—General', 'previousClose': 99.21, 'regularMarketOpen': 100, 'twoHundredDayAverage': 92.25281, 'trailingAnnualDividendYield': 0.047575846, 'payoutRatio': 0.9935, 'volume24Hr': None, 'regularMarketDayHigh': 100.29, 'navPrice': None, 'averageDailyVolume10Day': 9644342, 'totalAssets': None, 'regularMarketPreviousClose': 99.21, 'fiftyDayAverage': 88.721664, 'trailingAnnualDividendRate': 4.72, 'open': 100, 'toCurrency': None, 'averageVolume10days': 9644342, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 5.2, 'exDividendDate': 1610582400, 'beta': 0.68602, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 98.68, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 21.5923, 'regularMarketVolume': 8759351, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 174224015360, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 8093469, 'priceToSalesTrailing12Months': 4.285954, 'dayLow': 98.68, 'ask': 98.87, 'ytdReturn': None, 'askSize': 800, 'volume': 8759351, 'fiftyTwoWeekHigh': 101.28, 'forwardPE': 8.098442, 'fromCurrency': None, 'fiveYearAvgDividendYield': 4.09, 'fiftyTwoWeekLow': 62.55, 'bid': 98.75, 'tradeable': False, 'dividendYield': 0.052399997, 'bidSize': 900, 'dayHigh': 100.29, 'exchange': 'NYQ', 'shortName': 'AbbVie Inc.', 'longName': 'AbbVie Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABBV', 'messageBoardId': 'finmb_141885706', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.256, 'beta3Year': None, 'profitMargins': 0.18157, 'enterpriseToEbitda': 13.842, '52WeekChange': 0.1377294, 'morningStarRiskRating': None, 'forwardEps': 12.19, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1764829952, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 8.65, 'sharesShort': 12838422, 'sharesPercentSharesOut': 0.0073, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.70075, 'netIncomeToCommon': 7324000256, 'trailingEps': 4.572, 'lastDividendValue': 1.18, 'SandP52WeekChange': 0.16119564, 'priceToBook': 11.412718, 'heldPercentInsiders': 0.00102, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.64, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1741869537, 'enterpriseValue': 254306664448, 'threeYearAverageReturn': None, 'lastSplitDate': None, 'lastSplitFactor': None, 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.225, 'dateShortInterest': 1604016000, 'pegRatio': 1.02, 'lastCapGain': None, 'shortPercentOfFloat': 0.0073, 'sharesShortPriorMonth': 12944987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 100, 'logo_url': 'https://logo.clearbit.com/abbvie.com'}\n",
            "{'zip': '01923', 'sector': 'Healthcare', 'fullTimeEmployees': 1536, 'longBusinessSummary': 'Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.', 'city': 'Danvers', 'phone': '978 646 1400', 'state': 'MA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abiomed.com', 'maxAge': 1, 'address1': '22 Cherry Hill Drive', 'fax': '978 777 8411', 'industry': 'Medical Devices', 'previousClose': 269.93, 'regularMarketOpen': 268.34, 'twoHundredDayAverage': 264.68497, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 269.56, 'navPrice': None, 'averageDailyVolume10Day': 233914, 'totalAssets': None, 'regularMarketPreviousClose': 269.93, 'fiftyDayAverage': 272.60556, 'trailingAnnualDividendRate': None, 'open': 268.34, 'toCurrency': None, 'averageVolume10days': 233914, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': None, 'beta': 1.425591, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 263.18, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.507687, 'regularMarketVolume': 151912, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 12030003200, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 306549, 'priceToSalesTrailing12Months': 14.983992, 'dayLow': 263.18, 'ask': 295, 'ytdReturn': None, 'askSize': 800, 'volume': 151912, 'fiftyTwoWeekHigh': 319.19, 'forwardPE': 52.19804, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 119.01, 'bid': 265.77, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 269.56, 'exchange': 'NMS', 'shortName': 'ABIOMED, Inc.', 'longName': 'Abiomed, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABMD', 'messageBoardId': 'finmb_247589', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 14.544, 'beta3Year': None, 'profitMargins': 0.25884, 'enterpriseToEbitda': 47.081, '52WeekChange': 0.45711195, 'morningStarRiskRating': None, 'forwardEps': 5.1, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 45189900, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 26.165, 'sharesShort': 2264731, 'sharesPercentSharesOut': 0.050100002, 'fundFamily': None, 'lastFiscalYearEnd': 1585612800, 'heldPercentInstitutions': 0.97622, 'netIncomeToCommon': 207816000, 'trailingEps': 4.55, 'lastDividendValue': None, 'SandP52WeekChange': 0.16119564, 'priceToBook': 10.174278, 'heldPercentInsiders': 0.023629999, 'nextFiscalYearEnd': 1648684800, 'mostRecentQuarter': 1601424000, 'shortRatio': 6.8, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 44184860, 'enterpriseValue': 11676511232, 'threeYearAverageReturn': None, 'lastSplitDate': 970444800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': None, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 3.76, 'dateShortInterest': 1604016000, 'pegRatio': 3.49, 'lastCapGain': None, 'shortPercentOfFloat': 0.0575, 'sharesShortPriorMonth': 2569077, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 268.34, 'logo_url': 'https://logo.clearbit.com/abiomed.com'}\n",
            "{'zip': '90405', 'sector': 'Communication Services', 'fullTimeEmployees': 9080, 'longBusinessSummary': \"Activision Blizzard, Inc., together with its subsidiaries, develops and distributes content and services on video game consoles, personal computers (PC), and mobile devices in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision Publishing, Inc.; Blizzard Entertainment, Inc.; and King Digital Entertainment. It develops, publishes, and sells interactive software products and entertainment content for the console and PC platforms through retail and digital channels, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies; and offer downloadable content. The company also maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games; and develops and publishes interactive entertainment content and services primarily on mobile platforms, such as Android and iOS, as well as distributes its content and services on the PC platform primarily through Facebook. In addition, it operate esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, and Candy Crush. It serves retailers and distributors, including mass-market retailers, first party digital storefronts, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. Activision Blizzard, Inc. was incorporated in 1979 and is headquartered in Santa Monica, California.\", 'city': 'Santa Monica', 'phone': '310 255 2000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.activisionblizzard.com', 'maxAge': 1, 'address1': '3100 Ocean Park Boulevard', 'industry': 'Electronic Gaming & Multimedia', 'previousClose': 77.11, 'regularMarketOpen': 76.9453, 'twoHundredDayAverage': 78.187195, 'trailingAnnualDividendYield': 0.0053170794, 'payoutRatio': 0.1439, 'volume24Hr': None, 'regularMarketDayHigh': 77.07, 'navPrice': None, 'averageDailyVolume10Day': 7492800, 'totalAssets': None, 'regularMarketPreviousClose': 77.11, 'fiftyDayAverage': 79.06084, 'trailingAnnualDividendRate': 0.41, 'open': 76.9453, 'toCurrency': None, 'averageVolume10days': 7492800, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 0.41, 'exDividendDate': 1586822400, 'beta': 0.701803, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 75.2786, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 26.500526, 'regularMarketVolume': 9161595, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 58350706688, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 6290701, 'priceToSalesTrailing12Months': 7.6175857, 'dayLow': 75.2786, 'ask': 75.7, 'ytdReturn': None, 'askSize': 800, 'volume': 9161595, 'fiftyTwoWeekHigh': 87.73, 'forwardPE': 21.327684, 'fromCurrency': None, 'fiveYearAvgDividendYield': 0.6, 'fiftyTwoWeekLow': 50.51, 'bid': 75.22, 'tradeable': False, 'dividendYield': 0.0053, 'bidSize': 900, 'dayHigh': 77.07, 'exchange': 'NMS', 'shortName': 'Activision Blizzard, Inc', 'longName': 'Activision Blizzard, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ATVI', 'messageBoardId': 'finmb_4222231', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 7.258, 'beta3Year': None, 'profitMargins': 0.2889, 'enterpriseToEbitda': 19.178, '52WeekChange': 0.42558694, 'morningStarRiskRating': None, 'forwardEps': 3.54, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 772857024, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 18.61, 'sharesShort': 8541130, 'sharesPercentSharesOut': 0.0111, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.89987, 'netIncomeToCommon': 2212999936, 'trailingEps': 2.849, 'lastDividendValue': 0.41, 'SandP52WeekChange': 0.16119564, 'priceToBook': 4.0569587, 'heldPercentInsiders': 0.012159999, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.46, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 764595342, 'enterpriseValue': 55597019136, 'threeYearAverageReturn': None, 'lastSplitDate': 1220832000, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1586822400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 1.961, 'dateShortInterest': 1604016000, 'pegRatio': 0.92, 'lastCapGain': None, 'shortPercentOfFloat': 0.0112, 'sharesShortPriorMonth': 9473578, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 76.9453, 'logo_url': 'https://logo.clearbit.com/activisionblizzard.com'}\n",
            "{'zip': '95110-2704', 'sector': 'Technology', 'fullTimeEmployees': 22634, 'longBusinessSummary': \"Adobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, teams, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves content creators, experience designers, app developers, enthusiasts, students, social media users, and creative professionals, as well as marketing departments and agencies, companies and publishers. The company's Digital Experience segment offers products, services, and solutions for creating, managing, executing, measuring, monetizing and optimizing customer experiences from advertising to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, marketing executives, information management and technology executives, product development executives, and sales and support executives. Its Publishing segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.\", 'city': 'San Jose', 'phone': '408-536-6000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.adobe.com', 'maxAge': 1, 'address1': '345 Park Avenue', 'fax': '408-537-6000', 'industry': 'Software—Infrastructure', 'previousClose': 467.95, 'regularMarketOpen': 466.71, 'twoHundredDayAverage': 447.6538, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 467.86, 'navPrice': None, 'averageDailyVolume10Day': 3027171, 'totalAssets': None, 'regularMarketPreviousClose': 467.95, 'fiftyDayAverage': 481.97556, 'trailingAnnualDividendRate': None, 'open': 466.71, 'toCurrency': None, 'averageVolume10days': 3027171, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': 1111622400, 'beta': 1.019165, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 459.26, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 57.86776, 'regularMarketVolume': 2063159, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 220416491520, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 3051052, 'priceToSalesTrailing12Months': 17.723644, 'dayLow': 459.26, 'ask': 460.7, 'ytdReturn': None, 'askSize': 1000, 'volume': 2063159, 'fiftyTwoWeekHigh': 536.88, 'forwardPE': 41.13429, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 255.13, 'bid': 458.75, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 467.86, 'exchange': 'NMS', 'shortName': 'Adobe Inc.', 'longName': 'Adobe Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ADBE', 'messageBoardId': 'finmb_24321', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 18.007, 'beta3Year': None, 'profitMargins': 0.3105, 'enterpriseToEbitda': 49.123, '52WeekChange': 0.55931354, 'morningStarRiskRating': None, 'forwardEps': 11.17, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 479719008, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 24.402, 'sharesShort': 4643770, 'sharesPercentSharesOut': 0.0097, 'fundFamily': None, 'lastFiscalYearEnd': 1574985600, 'heldPercentInstitutions': 0.86247003, 'netIncomeToCommon': 3861457920, 'trailingEps': 7.94, 'lastDividendValue': 0.0065, 'SandP52WeekChange': 0.16119564, 'priceToBook': 18.829193, 'heldPercentInsiders': 0.0031, 'nextFiscalYearEnd': 1638144000, 'mostRecentQuarter': 1598572800, 'shortRatio': 2.07, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 478116722, 'enterpriseValue': 223946506240, 'threeYearAverageReturn': None, 'lastSplitDate': 1116892800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1111622400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.204, 'dateShortInterest': 1604016000, 'pegRatio': 2.7, 'lastCapGain': None, 'shortPercentOfFloat': 0.0097, 'sharesShortPriorMonth': 4366911, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 466.71, 'logo_url': 'https://logo.clearbit.com/adobe.com'}\n",
            "Time taken: : 5.6557700634002686\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PeudwWh3iT_M",
        "outputId": "80e726ac-2548-4b93-8f82-3c85ffa8add6"
      },
      "source": [
        "import time\n",
        "import concurrent.futures\n",
        "\n",
        "started = time.time()\n",
        "\n",
        "companies = ['ABT', 'ABBV', 'ABMD', 'ATVI', 'ADBE']\n",
        "\n",
        "size = 5\n",
        "with concurrent.futures.ThreadPoolExecutor(size) as thp:\n",
        "    thp.map(print_company_info, companies)\n",
        "elapsed = time.time()\n",
        "\n",
        "print('Time taken: :', elapsed - started)"
      ],
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "{'zip': '01923', 'sector': 'Healthcare', 'fullTimeEmployees': 1536, 'longBusinessSummary': 'Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.', 'city': 'Danvers', 'phone': '978 646 1400', 'state': 'MA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abiomed.com', 'maxAge': 1, 'address1': '22 Cherry Hill Drive', 'fax': '978 777 8411', 'industry': 'Medical Devices', 'previousClose': 269.93, 'regularMarketOpen': 268.34, 'twoHundredDayAverage': 264.68497, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 269.56, 'navPrice': None, 'averageDailyVolume10Day': 233914, 'totalAssets': None, 'regularMarketPreviousClose': 269.93, 'fiftyDayAverage': 272.60556, 'trailingAnnualDividendRate': None, 'open': 268.34, 'toCurrency': None, 'averageVolume10days': 233914, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': None, 'beta': 1.425591, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 263.18, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.507687, 'regularMarketVolume': 151912, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 12030003200, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 306549, 'priceToSalesTrailing12Months': 14.983992, 'dayLow': 263.18, 'ask': 295, 'ytdReturn': None, 'askSize': 800, 'volume': 151912, 'fiftyTwoWeekHigh': 319.19, 'forwardPE': 52.19804, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 119.01, 'bid': 265.77, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 269.56, 'exchange': 'NMS', 'shortName': 'ABIOMED, Inc.', 'longName': 'Abiomed, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABMD', 'messageBoardId': 'finmb_247589', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 14.544, 'beta3Year': None, 'profitMargins': 0.25884, 'enterpriseToEbitda': 47.081, '52WeekChange': 0.45711195, 'morningStarRiskRating': None, 'forwardEps': 5.1, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 45189900, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 26.165, 'sharesShort': 2264731, 'sharesPercentSharesOut': 0.050100002, 'fundFamily': None, 'lastFiscalYearEnd': 1585612800, 'heldPercentInstitutions': 0.97622, 'netIncomeToCommon': 207816000, 'trailingEps': 4.55, 'lastDividendValue': None, 'SandP52WeekChange': 0.16119564, 'priceToBook': 10.174278, 'heldPercentInsiders': 0.023629999, 'nextFiscalYearEnd': 1648684800, 'mostRecentQuarter': 1601424000, 'shortRatio': 6.8, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 44184860, 'enterpriseValue': 11676511232, 'threeYearAverageReturn': None, 'lastSplitDate': 970444800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': None, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 3.76, 'dateShortInterest': 1604016000, 'pegRatio': 3.49, 'lastCapGain': None, 'shortPercentOfFloat': 0.0575, 'sharesShortPriorMonth': 2569077, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 268.34, 'logo_url': 'https://logo.clearbit.com/abiomed.com'}\n",
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 107000, 'longBusinessSummary': \"Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '224 667 6100', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbott.com', 'maxAge': 1, 'address1': '100 Abbott Park Road', 'industry': 'Medical Devices', 'address2': 'Department 377 Building AP6A-1, Abbott park', 'previousClose': 113.06, 'regularMarketOpen': 113.67, 'twoHundredDayAverage': 100.25935, 'trailingAnnualDividendYield': 0.012736601, 'payoutRatio': 0.7447, 'volume24Hr': None, 'regularMarketDayHigh': 113.71, 'navPrice': None, 'averageDailyVolume10Day': 5414542, 'totalAssets': None, 'regularMarketPreviousClose': 113.06, 'fiftyDayAverage': 109.12278, 'trailingAnnualDividendRate': 1.44, 'open': 113.67, 'toCurrency': None, 'averageVolume10days': 5414542, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 1.44, 'exDividendDate': 1602633600, 'beta': 0.893461, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 109.75, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.04865, 'regularMarketVolume': 4318732, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 194551939072, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 5585046, 'priceToSalesTrailing12Months': 6.038048, 'dayLow': 109.75, 'ask': 110.49, 'ytdReturn': None, 'askSize': 1200, 'volume': 4318732, 'fiftyTwoWeekHigh': 115.14, 'forwardPE': 24.947725, 'fromCurrency': None, 'fiveYearAvgDividendYield': 1.89, 'fiftyTwoWeekLow': 61.61, 'bid': 109.69, 'tradeable': False, 'dividendYield': 0.0127, 'bidSize': 800, 'dayHigh': 113.71, 'exchange': 'NYQ', 'shortName': 'Abbott Laboratories', 'longName': 'Abbott Laboratories', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABT', 'messageBoardId': 'finmb_247483', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.655, 'beta3Year': None, 'profitMargins': 0.10496, 'enterpriseToEbitda': 27.409, '52WeekChange': 0.3477173, 'morningStarRiskRating': None, 'forwardEps': 4.4, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1772359936, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 17.709, 'sharesShort': 9924969, 'sharesPercentSharesOut': 0.0056, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.75431997, 'netIncomeToCommon': 3345999872, 'trailingEps': 1.891, 'lastDividendValue': 0.36, 'SandP52WeekChange': 0.16119564, 'priceToBook': 6.198543, 'heldPercentInsiders': 0.00696, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 2.03, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1758820739, 'enterpriseValue': 214424207360, 'threeYearAverageReturn': None, 'lastSplitDate': 1357084800, 'lastSplitFactor': '10000:4798', 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.283, 'dateShortInterest': 1604016000, 'pegRatio': 2.39, 'lastCapGain': None, 'shortPercentOfFloat': 0.0057, 'sharesShortPriorMonth': 9437987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 113.67, 'logo_url': 'https://logo.clearbit.com/abbott.com'}{'zip': '90405', 'sector': 'Communication Services', 'fullTimeEmployees': 9080, 'longBusinessSummary': \"Activision Blizzard, Inc., together with its subsidiaries, develops and distributes content and services on video game consoles, personal computers (PC), and mobile devices in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision Publishing, Inc.; Blizzard Entertainment, Inc.; and King Digital Entertainment. It develops, publishes, and sells interactive software products and entertainment content for the console and PC platforms through retail and digital channels, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies; and offer downloadable content. The company also maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games; and develops and publishes interactive entertainment content and services primarily on mobile platforms, such as Android and iOS, as well as distributes its content and services on the PC platform primarily through Facebook. In addition, it operate esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, and Candy Crush. It serves retailers and distributors, including mass-market retailers, first party digital storefronts, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. Activision Blizzard, Inc. was incorporated in 1979 and is headquartered in Santa Monica, California.\", 'city': 'Santa Monica', 'phone': '310 255 2000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.activisionblizzard.com', 'maxAge': 1, 'address1': '3100 Ocean Park Boulevard', 'industry': 'Electronic Gaming & Multimedia', 'previousClose': 77.11, 'regularMarketOpen': 76.9453, 'twoHundredDayAverage': 78.187195, 'trailingAnnualDividendYield': 0.0053170794, 'payoutRatio': 0.1439, 'volume24Hr': None, 'regularMarketDayHigh': 77.07, 'navPrice': None, 'averageDailyVolume10Day': 7492800, 'totalAssets': None, 'regularMarketPreviousClose': 77.11, 'fiftyDayAverage': 79.06084, 'trailingAnnualDividendRate': 0.41, 'open': 76.9453, 'toCurrency': None, 'averageVolume10days': 7492800, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 0.41, 'exDividendDate': 1586822400, 'beta': 0.701803, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 75.2786, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 26.500526, 'regularMarketVolume': 9161595, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 58350706688, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 6290701, 'priceToSalesTrailing12Months': 7.6175857, 'dayLow': 75.2786, 'ask': 75.7, 'ytdReturn': None, 'askSize': 800, 'volume': 9161595, 'fiftyTwoWeekHigh': 87.73, 'forwardPE': 21.327684, 'fromCurrency': None, 'fiveYearAvgDividendYield': 0.6, 'fiftyTwoWeekLow': 50.51, 'bid': 75.22, 'tradeable': False, 'dividendYield': 0.0053, 'bidSize': 900, 'dayHigh': 77.07, 'exchange': 'NMS', 'shortName': 'Activision Blizzard, Inc', 'longName': 'Activision Blizzard, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ATVI', 'messageBoardId': 'finmb_4222231', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 7.258, 'beta3Year': None, 'profitMargins': 0.2889, 'enterpriseToEbitda': 19.178, '52WeekChange': 0.42558694, 'morningStarRiskRating': None, 'forwardEps': 3.54, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 772857024, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 18.61, 'sharesShort': 8541130, 'sharesPercentSharesOut': 0.0111, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.89987, 'netIncomeToCommon': 2212999936, 'trailingEps': 2.849, 'lastDividendValue': 0.41, 'SandP52WeekChange': 0.16119564, 'priceToBook': 4.0569587, 'heldPercentInsiders': 0.012159999, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.46, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 764595342, 'enterpriseValue': 55597019136, 'threeYearAverageReturn': None, 'lastSplitDate': 1220832000, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1586822400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 1.961, 'dateShortInterest': 1604016000, 'pegRatio': 0.92, 'lastCapGain': None, 'shortPercentOfFloat': 0.0112, 'sharesShortPriorMonth': 9473578, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 76.9453, 'logo_url': 'https://logo.clearbit.com/activisionblizzard.com'}\n",
            "\n",
            "{'zip': '95110-2704', 'sector': 'Technology', 'fullTimeEmployees': 22634, 'longBusinessSummary': \"Adobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, teams, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves content creators, experience designers, app developers, enthusiasts, students, social media users, and creative professionals, as well as marketing departments and agencies, companies and publishers. The company's Digital Experience segment offers products, services, and solutions for creating, managing, executing, measuring, monetizing and optimizing customer experiences from advertising to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, marketing executives, information management and technology executives, product development executives, and sales and support executives. Its Publishing segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.\", 'city': 'San Jose', 'phone': '408-536-6000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.adobe.com', 'maxAge': 1, 'address1': '345 Park Avenue', 'fax': '408-537-6000', 'industry': 'Software—Infrastructure', 'previousClose': 467.95, 'regularMarketOpen': 466.71, 'twoHundredDayAverage': 447.6538, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 467.86, 'navPrice': None, 'averageDailyVolume10Day': 3027171, 'totalAssets': None, 'regularMarketPreviousClose': 467.95, 'fiftyDayAverage': 481.97556, 'trailingAnnualDividendRate': None, 'open': 466.71, 'toCurrency': None, 'averageVolume10days': 3027171, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': 1111622400, 'beta': 1.019165, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 459.26, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 57.86776, 'regularMarketVolume': 2063159, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 220416491520, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 3051052, 'priceToSalesTrailing12Months': 17.723644, 'dayLow': 459.26, 'ask': 460.7, 'ytdReturn': None, 'askSize': 1000, 'volume': 2063159, 'fiftyTwoWeekHigh': 536.88, 'forwardPE': 41.13429, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 255.13, 'bid': 458.75, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 467.86, 'exchange': 'NMS', 'shortName': 'Adobe Inc.', 'longName': 'Adobe Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ADBE', 'messageBoardId': 'finmb_24321', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 18.007, 'beta3Year': None, 'profitMargins': 0.3105, 'enterpriseToEbitda': 49.123, '52WeekChange': 0.55931354, 'morningStarRiskRating': None, 'forwardEps': 11.17, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 479719008, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 24.402, 'sharesShort': 4643770, 'sharesPercentSharesOut': 0.0097, 'fundFamily': None, 'lastFiscalYearEnd': 1574985600, 'heldPercentInstitutions': 0.86247003, 'netIncomeToCommon': 3861457920, 'trailingEps': 7.94, 'lastDividendValue': 0.0065, 'SandP52WeekChange': 0.16119564, 'priceToBook': 18.829193, 'heldPercentInsiders': 0.0031, 'nextFiscalYearEnd': 1638144000, 'mostRecentQuarter': 1598572800, 'shortRatio': 2.07, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 478116722, 'enterpriseValue': 223946506240, 'threeYearAverageReturn': None, 'lastSplitDate': 1116892800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1111622400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.204, 'dateShortInterest': 1604016000, 'pegRatio': 2.7, 'lastCapGain': None, 'shortPercentOfFloat': 0.0097, 'sharesShortPriorMonth': 4366911, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 466.71, 'logo_url': 'https://logo.clearbit.com/adobe.com'}\n",
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 47000, 'longBusinessSummary': \"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '847 932 7900', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbvie.com', 'maxAge': 1, 'address1': '1 North Waukegan Road', 'industry': 'Drug Manufacturers—General', 'previousClose': 99.21, 'regularMarketOpen': 100, 'twoHundredDayAverage': 92.25281, 'trailingAnnualDividendYield': 0.047575846, 'payoutRatio': 0.9935, 'volume24Hr': None, 'regularMarketDayHigh': 100.29, 'navPrice': None, 'averageDailyVolume10Day': 9644342, 'totalAssets': None, 'regularMarketPreviousClose': 99.21, 'fiftyDayAverage': 88.721664, 'trailingAnnualDividendRate': 4.72, 'open': 100, 'toCurrency': None, 'averageVolume10days': 9644342, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 5.2, 'exDividendDate': 1610582400, 'beta': 0.68602, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 98.68, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 21.5923, 'regularMarketVolume': 8759351, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 174224015360, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 8093469, 'priceToSalesTrailing12Months': 4.285954, 'dayLow': 98.68, 'ask': 98.87, 'ytdReturn': None, 'askSize': 800, 'volume': 8759351, 'fiftyTwoWeekHigh': 101.28, 'forwardPE': 8.098442, 'fromCurrency': None, 'fiveYearAvgDividendYield': 4.09, 'fiftyTwoWeekLow': 62.55, 'bid': 98.75, 'tradeable': False, 'dividendYield': 0.052399997, 'bidSize': 900, 'dayHigh': 100.29, 'exchange': 'NYQ', 'shortName': 'AbbVie Inc.', 'longName': 'AbbVie Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABBV', 'messageBoardId': 'finmb_141885706', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.256, 'beta3Year': None, 'profitMargins': 0.18157, 'enterpriseToEbitda': 13.842, '52WeekChange': 0.1377294, 'morningStarRiskRating': None, 'forwardEps': 12.19, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1764829952, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 8.65, 'sharesShort': 12838422, 'sharesPercentSharesOut': 0.0073, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.70075, 'netIncomeToCommon': 7324000256, 'trailingEps': 4.572, 'lastDividendValue': 1.18, 'SandP52WeekChange': 0.16119564, 'priceToBook': 11.412718, 'heldPercentInsiders': 0.00102, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.64, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1741869537, 'enterpriseValue': 254306664448, 'threeYearAverageReturn': None, 'lastSplitDate': None, 'lastSplitFactor': None, 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.225, 'dateShortInterest': 1604016000, 'pegRatio': 1.02, 'lastCapGain': None, 'shortPercentOfFloat': 0.0073, 'sharesShortPriorMonth': 12944987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 100, 'logo_url': 'https://logo.clearbit.com/abbvie.com'}\n",
            "Time taken: : 1.3449223041534424\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 514
        },
        "id": "Ml6v3EokmnT1",
        "outputId": "9007db9d-c0c5-480c-9bb8-413ff19df4f1"
      },
      "source": [
        "import asyncio\n",
        "import time\n",
        "\n",
        "def print_company_info(company):\n",
        "    ticker = yf.Ticker(company)\n",
        "    info = ticker.get_info()\n",
        "    print(info)\n",
        "    \n",
        "companies = ['ABT', 'ABBV', 'ABMD', 'ATVI', 'ADBE']\n",
        "tasks = []\n",
        "event_loop = asyncio.get_event_loop()\n",
        "\n",
        "for company in companies:\n",
        "    #Not calling the functions here, we are storing an awaitable functions in an array\n",
        "    tasks.append((print_company_info(company)))\n",
        "    \n",
        "started = time.time()\n",
        "event_loop.run_until_complete(asyncio.wait(tasks))\n",
        "elapsed = time.time()"
      ],
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 107000, 'longBusinessSummary': \"Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '224 667 6100', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbott.com', 'maxAge': 1, 'address1': '100 Abbott Park Road', 'industry': 'Medical Devices', 'address2': 'Department 377 Building AP6A-1, Abbott park', 'previousClose': 113.06, 'regularMarketOpen': 113.67, 'twoHundredDayAverage': 100.25935, 'trailingAnnualDividendYield': 0.012736601, 'payoutRatio': 0.7447, 'volume24Hr': None, 'regularMarketDayHigh': 113.71, 'navPrice': None, 'averageDailyVolume10Day': 5414542, 'totalAssets': None, 'regularMarketPreviousClose': 113.06, 'fiftyDayAverage': 109.12278, 'trailingAnnualDividendRate': 1.44, 'open': 113.67, 'toCurrency': None, 'averageVolume10days': 5414542, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 1.44, 'exDividendDate': 1602633600, 'beta': 0.893461, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 109.75, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.04865, 'regularMarketVolume': 4318732, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 194551939072, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 5585046, 'priceToSalesTrailing12Months': 6.038048, 'dayLow': 109.75, 'ask': 110.49, 'ytdReturn': None, 'askSize': 1200, 'volume': 4318732, 'fiftyTwoWeekHigh': 115.14, 'forwardPE': 24.947725, 'fromCurrency': None, 'fiveYearAvgDividendYield': 1.89, 'fiftyTwoWeekLow': 61.61, 'bid': 109.69, 'tradeable': False, 'dividendYield': 0.0127, 'bidSize': 800, 'dayHigh': 113.71, 'exchange': 'NYQ', 'shortName': 'Abbott Laboratories', 'longName': 'Abbott Laboratories', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABT', 'messageBoardId': 'finmb_247483', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.655, 'beta3Year': None, 'profitMargins': 0.10496, 'enterpriseToEbitda': 27.409, '52WeekChange': 0.3477173, 'morningStarRiskRating': None, 'forwardEps': 4.4, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1772359936, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 17.709, 'sharesShort': 9924969, 'sharesPercentSharesOut': 0.0056, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.75431997, 'netIncomeToCommon': 3345999872, 'trailingEps': 1.891, 'lastDividendValue': 0.36, 'SandP52WeekChange': 0.16119564, 'priceToBook': 6.198543, 'heldPercentInsiders': 0.00696, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 2.03, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1758820739, 'enterpriseValue': 214424207360, 'threeYearAverageReturn': None, 'lastSplitDate': 1357084800, 'lastSplitFactor': '10000:4798', 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.283, 'dateShortInterest': 1604016000, 'pegRatio': 2.39, 'lastCapGain': None, 'shortPercentOfFloat': 0.0057, 'sharesShortPriorMonth': 9437987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 113.67, 'logo_url': 'https://logo.clearbit.com/abbott.com'}\n",
            "{'zip': '60064', 'sector': 'Healthcare', 'fullTimeEmployees': 47000, 'longBusinessSummary': \"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.\", 'city': 'North Chicago', 'phone': '847 932 7900', 'state': 'IL', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abbvie.com', 'maxAge': 1, 'address1': '1 North Waukegan Road', 'industry': 'Drug Manufacturers—General', 'previousClose': 99.21, 'regularMarketOpen': 100, 'twoHundredDayAverage': 92.25281, 'trailingAnnualDividendYield': 0.047575846, 'payoutRatio': 0.9935, 'volume24Hr': None, 'regularMarketDayHigh': 100.29, 'navPrice': None, 'averageDailyVolume10Day': 9644657, 'totalAssets': None, 'regularMarketPreviousClose': 99.21, 'fiftyDayAverage': 88.721664, 'trailingAnnualDividendRate': 4.72, 'open': 100, 'toCurrency': None, 'averageVolume10days': 9644657, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 5.2, 'exDividendDate': 1610582400, 'beta': 0.68602, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 98.68, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 21.5923, 'regularMarketVolume': 8759351, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 174224015360, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 8093503, 'priceToSalesTrailing12Months': 4.285954, 'dayLow': 98.68, 'ask': 98.87, 'ytdReturn': None, 'askSize': 800, 'volume': 8759351, 'fiftyTwoWeekHigh': 101.28, 'forwardPE': 8.098442, 'fromCurrency': None, 'fiveYearAvgDividendYield': 4.09, 'fiftyTwoWeekLow': 62.55, 'bid': 98.75, 'tradeable': False, 'dividendYield': 0.052399997, 'bidSize': 900, 'dayHigh': 100.29, 'exchange': 'NYQ', 'shortName': 'AbbVie Inc.', 'longName': 'AbbVie Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABBV', 'messageBoardId': 'finmb_141885706', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 6.256, 'beta3Year': None, 'profitMargins': 0.18157, 'enterpriseToEbitda': 13.842, '52WeekChange': 0.1377294, 'morningStarRiskRating': None, 'forwardEps': 12.19, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 1764829952, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 8.65, 'sharesShort': 12838422, 'sharesPercentSharesOut': 0.0073, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.70075, 'netIncomeToCommon': 7324000256, 'trailingEps': 4.572, 'lastDividendValue': 1.18, 'SandP52WeekChange': 0.16119564, 'priceToBook': 11.412718, 'heldPercentInsiders': 0.00102, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.64, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 1741869537, 'enterpriseValue': 254306664448, 'threeYearAverageReturn': None, 'lastSplitDate': None, 'lastSplitFactor': None, 'legalType': None, 'lastDividendDate': 1602633600, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.225, 'dateShortInterest': 1604016000, 'pegRatio': 1.02, 'lastCapGain': None, 'shortPercentOfFloat': 0.0073, 'sharesShortPriorMonth': 12944987, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 100, 'logo_url': 'https://logo.clearbit.com/abbvie.com'}\n",
            "{'zip': '01923', 'sector': 'Healthcare', 'fullTimeEmployees': 1536, 'longBusinessSummary': 'Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.', 'city': 'Danvers', 'phone': '978 646 1400', 'state': 'MA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.abiomed.com', 'maxAge': 1, 'address1': '22 Cherry Hill Drive', 'fax': '978 777 8411', 'industry': 'Medical Devices', 'previousClose': 269.93, 'regularMarketOpen': 268.34, 'twoHundredDayAverage': 264.68497, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 269.56, 'navPrice': None, 'averageDailyVolume10Day': 233914, 'totalAssets': None, 'regularMarketPreviousClose': 269.93, 'fiftyDayAverage': 272.60556, 'trailingAnnualDividendRate': None, 'open': 268.34, 'toCurrency': None, 'averageVolume10days': 233914, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': None, 'beta': 1.425591, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 263.18, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 58.507687, 'regularMarketVolume': 151912, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 12030003200, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 306549, 'priceToSalesTrailing12Months': 14.983992, 'dayLow': 263.18, 'ask': 295, 'ytdReturn': None, 'askSize': 800, 'volume': 151912, 'fiftyTwoWeekHigh': 319.19, 'forwardPE': 52.19804, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 119.01, 'bid': 265.77, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 269.56, 'exchange': 'NMS', 'shortName': 'ABIOMED, Inc.', 'longName': 'Abiomed, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ABMD', 'messageBoardId': 'finmb_247589', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 14.544, 'beta3Year': None, 'profitMargins': 0.25884, 'enterpriseToEbitda': 47.081, '52WeekChange': 0.45711195, 'morningStarRiskRating': None, 'forwardEps': 5.1, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 45189900, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 26.165, 'sharesShort': 2264731, 'sharesPercentSharesOut': 0.050100002, 'fundFamily': None, 'lastFiscalYearEnd': 1585612800, 'heldPercentInstitutions': 0.97622, 'netIncomeToCommon': 207816000, 'trailingEps': 4.55, 'lastDividendValue': None, 'SandP52WeekChange': 0.16119564, 'priceToBook': 10.174278, 'heldPercentInsiders': 0.023629999, 'nextFiscalYearEnd': 1648684800, 'mostRecentQuarter': 1601424000, 'shortRatio': 6.8, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 44184860, 'enterpriseValue': 11676511232, 'threeYearAverageReturn': None, 'lastSplitDate': 970444800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': None, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 3.76, 'dateShortInterest': 1604016000, 'pegRatio': 3.49, 'lastCapGain': None, 'shortPercentOfFloat': 0.0575, 'sharesShortPriorMonth': 2569077, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 268.34, 'logo_url': 'https://logo.clearbit.com/abiomed.com'}\n",
            "{'zip': '90405', 'sector': 'Communication Services', 'fullTimeEmployees': 9080, 'longBusinessSummary': \"Activision Blizzard, Inc., together with its subsidiaries, develops and distributes content and services on video game consoles, personal computers (PC), and mobile devices in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision Publishing, Inc.; Blizzard Entertainment, Inc.; and King Digital Entertainment. It develops, publishes, and sells interactive software products and entertainment content for the console and PC platforms through retail and digital channels, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies; and offer downloadable content. The company also maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games; and develops and publishes interactive entertainment content and services primarily on mobile platforms, such as Android and iOS, as well as distributes its content and services on the PC platform primarily through Facebook. In addition, it operate esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, and Candy Crush. It serves retailers and distributors, including mass-market retailers, first party digital storefronts, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. Activision Blizzard, Inc. was incorporated in 1979 and is headquartered in Santa Monica, California.\", 'city': 'Santa Monica', 'phone': '310 255 2000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.activisionblizzard.com', 'maxAge': 1, 'address1': '3100 Ocean Park Boulevard', 'industry': 'Electronic Gaming & Multimedia', 'previousClose': 77.11, 'regularMarketOpen': 76.9453, 'twoHundredDayAverage': 78.187195, 'trailingAnnualDividendYield': 0.0053170794, 'payoutRatio': 0.1439, 'volume24Hr': None, 'regularMarketDayHigh': 77.07, 'navPrice': None, 'averageDailyVolume10Day': 7492800, 'totalAssets': None, 'regularMarketPreviousClose': 77.11, 'fiftyDayAverage': 79.06084, 'trailingAnnualDividendRate': 0.41, 'open': 76.9453, 'toCurrency': None, 'averageVolume10days': 7492800, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': 0.41, 'exDividendDate': 1586822400, 'beta': 0.701803, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 75.2786, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 26.500526, 'regularMarketVolume': 9161595, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 58350706688, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 6290701, 'priceToSalesTrailing12Months': 7.6175857, 'dayLow': 75.2786, 'ask': 75.7, 'ytdReturn': None, 'askSize': 800, 'volume': 9161595, 'fiftyTwoWeekHigh': 87.73, 'forwardPE': 21.327684, 'fromCurrency': None, 'fiveYearAvgDividendYield': 0.6, 'fiftyTwoWeekLow': 50.51, 'bid': 75.22, 'tradeable': False, 'dividendYield': 0.0053, 'bidSize': 900, 'dayHigh': 77.07, 'exchange': 'NMS', 'shortName': 'Activision Blizzard, Inc', 'longName': 'Activision Blizzard, Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ATVI', 'messageBoardId': 'finmb_4222231', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 7.258, 'beta3Year': None, 'profitMargins': 0.2889, 'enterpriseToEbitda': 19.178, '52WeekChange': 0.42558694, 'morningStarRiskRating': None, 'forwardEps': 3.54, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 772857024, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 18.61, 'sharesShort': 8541130, 'sharesPercentSharesOut': 0.0111, 'fundFamily': None, 'lastFiscalYearEnd': 1577750400, 'heldPercentInstitutions': 0.89987, 'netIncomeToCommon': 2212999936, 'trailingEps': 2.849, 'lastDividendValue': 0.41, 'SandP52WeekChange': 0.16119564, 'priceToBook': 4.0569587, 'heldPercentInsiders': 0.012159999, 'nextFiscalYearEnd': 1640908800, 'mostRecentQuarter': 1601424000, 'shortRatio': 1.46, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 764595342, 'enterpriseValue': 55597019136, 'threeYearAverageReturn': None, 'lastSplitDate': 1220832000, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1586822400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 1.961, 'dateShortInterest': 1604016000, 'pegRatio': 0.92, 'lastCapGain': None, 'shortPercentOfFloat': 0.0112, 'sharesShortPriorMonth': 9473578, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 76.9453, 'logo_url': 'https://logo.clearbit.com/activisionblizzard.com'}\n",
            "{'zip': '95110-2704', 'sector': 'Technology', 'fullTimeEmployees': 22634, 'longBusinessSummary': \"Adobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, teams, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves content creators, experience designers, app developers, enthusiasts, students, social media users, and creative professionals, as well as marketing departments and agencies, companies and publishers. The company's Digital Experience segment offers products, services, and solutions for creating, managing, executing, measuring, monetizing and optimizing customer experiences from advertising to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, marketing executives, information management and technology executives, product development executives, and sales and support executives. Its Publishing segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.\", 'city': 'San Jose', 'phone': '408-536-6000', 'state': 'CA', 'country': 'United States', 'companyOfficers': [], 'website': 'http://www.adobe.com', 'maxAge': 1, 'address1': '345 Park Avenue', 'fax': '408-537-6000', 'industry': 'Software—Infrastructure', 'previousClose': 467.95, 'regularMarketOpen': 466.71, 'twoHundredDayAverage': 447.6538, 'trailingAnnualDividendYield': None, 'payoutRatio': 0, 'volume24Hr': None, 'regularMarketDayHigh': 467.86, 'navPrice': None, 'averageDailyVolume10Day': 3027171, 'totalAssets': None, 'regularMarketPreviousClose': 467.95, 'fiftyDayAverage': 481.97556, 'trailingAnnualDividendRate': None, 'open': 466.71, 'toCurrency': None, 'averageVolume10days': 3027171, 'expireDate': None, 'yield': None, 'algorithm': None, 'dividendRate': None, 'exDividendDate': 1111622400, 'beta': 1.019165, 'circulatingSupply': None, 'startDate': None, 'regularMarketDayLow': 459.26, 'priceHint': 2, 'currency': 'USD', 'trailingPE': 57.86776, 'regularMarketVolume': 2063159, 'lastMarket': None, 'maxSupply': None, 'openInterest': None, 'marketCap': 220416491520, 'volumeAllCurrencies': None, 'strikePrice': None, 'averageVolume': 3051052, 'priceToSalesTrailing12Months': 17.723644, 'dayLow': 459.26, 'ask': 460.7, 'ytdReturn': None, 'askSize': 1000, 'volume': 2063159, 'fiftyTwoWeekHigh': 536.88, 'forwardPE': 41.13429, 'fromCurrency': None, 'fiveYearAvgDividendYield': None, 'fiftyTwoWeekLow': 255.13, 'bid': 458.75, 'tradeable': False, 'dividendYield': None, 'bidSize': 1100, 'dayHigh': 467.86, 'exchange': 'NMS', 'shortName': 'Adobe Inc.', 'longName': 'Adobe Inc.', 'exchangeTimezoneName': 'America/New_York', 'exchangeTimezoneShortName': 'EST', 'isEsgPopulated': False, 'gmtOffSetMilliseconds': '-18000000', 'quoteType': 'EQUITY', 'symbol': 'ADBE', 'messageBoardId': 'finmb_24321', 'market': 'us_market', 'annualHoldingsTurnover': None, 'enterpriseToRevenue': 18.007, 'beta3Year': None, 'profitMargins': 0.3105, 'enterpriseToEbitda': 49.123, '52WeekChange': 0.55931354, 'morningStarRiskRating': None, 'forwardEps': 11.17, 'revenueQuarterlyGrowth': None, 'sharesOutstanding': 479719008, 'fundInceptionDate': None, 'annualReportExpenseRatio': None, 'bookValue': 24.402, 'sharesShort': 4643770, 'sharesPercentSharesOut': 0.0097, 'fundFamily': None, 'lastFiscalYearEnd': 1574985600, 'heldPercentInstitutions': 0.86247003, 'netIncomeToCommon': 3861457920, 'trailingEps': 7.94, 'lastDividendValue': 0.0065, 'SandP52WeekChange': 0.16119564, 'priceToBook': 18.829193, 'heldPercentInsiders': 0.0031, 'nextFiscalYearEnd': 1638144000, 'mostRecentQuarter': 1598572800, 'shortRatio': 2.07, 'sharesShortPreviousMonthDate': 1601424000, 'floatShares': 478116722, 'enterpriseValue': 223946506240, 'threeYearAverageReturn': None, 'lastSplitDate': 1116892800, 'lastSplitFactor': '2:1', 'legalType': None, 'lastDividendDate': 1111622400, 'morningStarOverallRating': None, 'earningsQuarterlyGrowth': 0.204, 'dateShortInterest': 1604016000, 'pegRatio': 2.7, 'lastCapGain': None, 'shortPercentOfFloat': 0.0097, 'sharesShortPriorMonth': 4366911, 'category': None, 'fiveYearAverageReturn': None, 'regularMarketPrice': 466.71, 'logo_url': 'https://logo.clearbit.com/adobe.com'}\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "error",
          "ename": "RuntimeError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mRuntimeError\u001b[0m                              Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-10-780b0f8c95ad>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     16\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m \u001b[0mstarted\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtime\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 18\u001b[0;31m \u001b[0mevent_loop\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrun_until_complete\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0masyncio\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwait\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtasks\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     19\u001b[0m \u001b[0melapsed\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtime\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.6/asyncio/base_events.py\u001b[0m in \u001b[0;36mrun_until_complete\u001b[0;34m(self, future)\u001b[0m\n\u001b[1;32m    469\u001b[0m         \u001b[0mfuture\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0madd_done_callback\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0m_run_until_complete_cb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    470\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 471\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrun_forever\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    472\u001b[0m         \u001b[0;32mexcept\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    473\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mnew_task\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mfuture\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdone\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mfuture\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcancelled\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.6/asyncio/base_events.py\u001b[0m in \u001b[0;36mrun_forever\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    423\u001b[0m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_check_closed\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    424\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mis_running\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 425\u001b[0;31m             \u001b[0;32mraise\u001b[0m \u001b[0mRuntimeError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'This event loop is already running'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    426\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mevents\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_get_running_loop\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    427\u001b[0m             raise RuntimeError(\n",
            "\u001b[0;31mRuntimeError\u001b[0m: This event loop is already running"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qhyrfGpSsudp",
        "outputId": "d1594658-4a4a-4af1-cab6-bfc79175a0a4"
      },
      "source": [
        "import time\n",
        "\n",
        "\n",
        "def increment(input):\n",
        "    for i in range(1000000):\n",
        "        input = input + 1\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    inputs = [1] * 100\n",
        "\n",
        "    \n",
        "    started = time.time()\n",
        "    for i in inputs:\n",
        "        increment(i)\n",
        "\n",
        "    # Time taken: : 35.019266843795776\n",
        "    elapsed = time.time()\n",
        "\n",
        "    print('Time taken Sequential:', elapsed - started)"
      ],
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Time taken Sequential: 5.373229503631592\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "H-gN7dgItaOE",
        "outputId": "8c8d6db0-7358-4807-a6af-771245f05d9c"
      },
      "source": [
        "import time\n",
        "from multiprocessing import Pool\n",
        "\n",
        "\n",
        "def increment(input):\n",
        "    for i in range(1000000):\n",
        "        input = input + 1\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    inputs = [1] * 100\n",
        "    pool = Pool(8)\n",
        "    started = time.time()\n",
        "    pool.map(increment, inputs)\n",
        "    \n",
        "\n",
        "    elapsed = time.time()\n",
        "    print('Time taken MultiProcess :', elapsed - started)\n",
        "\n",
        "    pool.close()"
      ],
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Time taken MultiProcess : 5.840396165847778\n"
          ],
          "name": "stdout"
        }
      ]
    }
  ]
}